Spravato Prior Authorization: A Patient Guide

Two clarifications are worth making. Prior authorization is a coverage decision, not a clinical one: a plan declining to pay is not a statement that treatment is inappropriate. And an approval is not a payment guarantee — payment still depends on your benefits, network status, correct billing, and the authorization remaining valid on the date of service.

The sequence below is the general pattern. Specific steps, forms, and portals differ by plan.

1. A clinician evaluates you and determines that Spravato is clinically appropriate.
2. The clinic verifies your benefits and identifies whether the drug falls under the medical or pharmacy benefit.
3. The clinic assembles clinical documentation, including diagnosis and prior treatment history.
4. The request is submitted to the plan on its required form or portal.
5. The plan reviews against its written criteria and may request additional information.
6. The plan issues a decision — approval for a defined period, or a denial with a stated reason.
7. If approved, scheduling proceeds within the authorized period; if denied, the appeals process begins.

No timeline is promised here on purpose. Decision speed is controlled by the insurer and varies with plan type, completeness of the submission, and whether an expedited review applies.

Requirements are plan-specific, but requests generally fall into these categories:

• Diagnosis, with the specific codes the plan requires.
• Documentation of the current depressive episode, often including onset and a symptom severity measure.
• Prior antidepressant trials — medication, dose, duration, and outcome.
• The proposed treatment plan, including dose and planned frequency.
• Confirmation that treatment will be delivered in a REMS-certified healthcare setting.
• Prescriber identification and, for some plans, prescriber specialty.
• Relevant medical history, including anything bearing on the labeled contraindications.

The clinical basis for several of these is the FDA-approved labeling — the indications, the setting requirement, and the contraindications. [FDA label] The rest are the plan’s own policy requirements.

This page deliberately does not state what any particular insurer requires. Those rules change and differ by plan; your plan’s policy document is the authority.

Treatment history is usually the deciding element, and it is the part patients can most directly influence. For each antidepressant tried during the current episode, the useful facts are:

• the medication name;
• the highest daily dose reached;
• approximate start and stop dates;
• how long it was taken at that dose;
• the outcome — inadequate response, side effects, or another reason for stopping.

“An adequate trial” generally means enough dose for enough time to judge the medication fairly. Trials that were stopped early, or never reached a therapeutic dose, may not count toward a plan’s requirement — which is not a judgment about you, just a documentation standard.

Pharmacy fill histories, patient portal records, and prior clinicians’ notes are the most common ways to reconstruct this. Your pharmacy can usually print a medication history covering several years.

Plans generally approve a bounded course rather than open-ended treatment — a number of sessions, a date range, or both. An initial approval may cover only the induction phase, with continuation reviewed separately.

Because the labeled schedule for treatment-resistant depression changes frequency over time — twice weekly, then weekly, then weekly or every two weeks — it is worth knowing whether your authorization is counted in sessions or in calendar time. [FDA label] See how often treatment is given.

Continuing beyond an authorization period requires a renewal request. Plans commonly ask for evidence of response and of continued clinical need, which may include repeat symptom measures and a summary of treatment to date.

Renewals are not automatic, and a lapse can interrupt scheduling even when treatment remains clinically appropriate. Two practical habits help: know your authorization end date, and ask the clinic how far in advance renewals are normally submitted.

A denial must come with a reason. Common reasons include insufficient documentation of prior trials, missing diagnosis detail, a request that falls outside the plan’s criteria, or a submission error.

Typical next steps:

1. Read the denial letter and identify the stated reason and the appeal deadline.
2. Ask the clinic whether the reason is correctable — missing records can often simply be supplied.
3. Request a peer-to-peer review, in which your clinician speaks directly with the plan's reviewing clinician.
4. File a formal internal appeal with additional documentation, within the deadline.
5. If internal appeals are exhausted, ask about external review by an independent reviewer.

Appeals succeed sometimes and fail sometimes; no outcome is promised here. What reliably helps is meeting deadlines and closing the specific gap the denial identifies.

Gathering these before your appointment shortens both the clinical evaluation and the authorization request. This is a preparation aid, not a determination of eligibility or coverage.

Prior authorization is a documentation exercise with deadlines. The plan sets criteria, the clinic submits evidence that you meet them, and the plan decides before treatment can be covered. The evidence almost always centers on your treatment history for the current episode.

Approvals expire, so renewal is part of the ongoing process rather than a one-time hurdle. Denials come with appeal rights and deadlines, and the fastest route through both is complete, accurate records assembled early.